Stockscreener 앱 받기
126.96
0.41%
0.52
시간 외 거래:
126.96
전일 마감가:
$126.44
열려 있는:
$126.39
하루 거래량:
523.17K
Relative Volume:
0.64
시가총액:
$7.47B
수익:
$633.51M
순이익/손실:
$-8.10M
주가수익비율:
-409.55
EPS:
-0.31
순현금흐름:
$131.26M
1주 성능:
+2.37%
1개월 성능:
+7.08%
6개월 성능:
-11.25%
1년 성능:
+5.68%
1일 변동 폭
$125.62
$128.19
1주일 범위
$121.44
$131.43
52주 변동 폭
$102.97
$182.52
Repligen Corp Stock (RGEN) Company Profile
명칭
Repligen Corp
전화
(781) 449-9560
주소
41 SEYON STREET, WALTHAM, MA
RGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
126.96 | 7.47B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
540.60 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
177.27 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
89.30 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
255.88 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
221.22 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | Evercore ISI | In-line |
| 2025-02-10 | 개시 | TD Cowen | Buy |
| 2024-12-17 | 개시 | Canaccord Genuity | Hold |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 개시 | Guggenheim | Neutral |
| 2023-12-04 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 개시 | Wells Fargo | Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-03-28 | 개시 | The Benchmark Company | Buy |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2021-10-14 | 개시 | Exane BNP Paribas | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-11-01 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 개시 | SVB Leerink | Outperform |
| 2019-08-28 | 재확인 | First Analysis Sec | Outperform |
| 2019-08-23 | 재개 | Stephens | Overweight |
| 2019-07-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | 업그레이드 | CL King | Neutral → Buy |
| 2018-11-12 | 다운그레이드 | CL King | Buy → Neutral |
| 2018-09-26 | 개시 | H.C. Wainwright | Neutral |
| 2017-12-08 | 개시 | Citigroup | Buy |
| 2017-12-05 | 개시 | JP Morgan | Overweight |
| 2017-11-13 | 개시 | CL King | Buy |
| 2017-10-02 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 개시 | William Blair | Outperform |
| 2017-02-13 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
Repligen Corp 주식(RGEN)의 최신 뉴스
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Yousif Capital Management LLC Has $2.01 Million Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Does Repligen Corp (RGEN) Have a Strong Pricing Power? - Insider Monkey
Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Parallel Advisors LLC Has $36,000 Stock Holdings in Repligen Co. (NASDAQ:RGEN) - Defense World
Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks - Yahoo Finance
Repligen at William Blair Conference: Innovation Drives Growth By Investing.com - Investing.com Canada
Repligen at William Blair Conference: Innovation Drives Growth - Investing.com
Repligen Corp (RGEN) Stock Price Up 5% on Jun 3 - GuruFocus
Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers - Yahoo Finance
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't? - Yahoo Finance
Repligen Corp (RGEN) Trading Down 3.33% on May 30 - GuruFocus
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report? - Yahoo Finance
Cetera Investment Advisers Has $436,000 Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen Corp (RGEN) Stock Price Up 4.35% on May 27 - GuruFocus
Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report - The Manila Times
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report - TradingView
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth challenges - Investing.com
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth challenges By Investing.com - Investing.com UK
Repligen Corporation to Present at William Blair Growth Conference - Yahoo Finance
Repligen at RBC Capital Markets: Strategic Growth Insights - Investing.com Australia
Insider Sell: Anthony Hunt Sells 26,447 Shares of Repligen Corp (RGEN) - GuruFocus
Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Mercer Global Advisors Inc. ADV Sells 1,039 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Contrasting Repligen (NASDAQ:RGEN) & Maze Therapeutics (NASDAQ:MAZE) - Defense World
Pioneering innovation in bioprocessing: Repligen’s growing impact in the area and symbiotic relationship with WWETB - Business Post
Why Repligen Corp Stock Might Make Sense If Bought Today - Stocksregister
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance
Stifel Financial Corp Grows Holdings in Repligen Co. (NASDAQ:RGEN) - Defense World
Things To Consider Before Buying Repligen Corp (NASDAQ: RGEN) - Stocksregister
Global Hollow Fiber Filtration Market Set to Witness - openPR.com
M&A activity dominates Q1, nearly 99% total med-tech deal value - BioWorld MedTech
Repligen (NASDAQ:RGEN) Upgraded to “Hold” at StockNews.com - Defense World
Investor’s Toolkit: Key Ratios for Assessing Repligen Corp (RGEN)’s Performance - DWinneX
Repligen Corporation to Present at Upcoming May Investor Conferences - Yahoo Finance
Repligen (NASDAQ:RGEN) Given Buy Rating at HC Wainwright - Defense World
Repligen (RGEN) Maintains Buy Rating with $180 Price Target | RG - GuruFocus
Repligen (RGEN) Maintains Buy Rating with $180 Price Target | RGEN Stock News - GuruFocus
Leerink Partnrs Has Pessimistic View of Repligen Q2 Earnings - Defense World
Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare - Insider Monkey
There is no doubt that Repligen Corp (RGEN) ticks all the boxes. - Sete News
Jim Cramer on Repligen Corporation (RGEN): ‘I’m Not Quite Ready to Stick My Neck Out on This One’ - Insider Monkey
Wolfe Research Upgrades Repligen (NASDAQ:RGEN) to “Outperform” - Defense World
BlackRock, Inc. Reduces Stake in Repligen Corp: An In-Depth Anal - GuruFocus
Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years - Insider Monkey
Deep Dive Into Repligen Stock: Analyst Perspectives (8 Ratings) - Benzinga
Wolfe Research Upgrades Repligen Corp (RGEN) to an Outperform from a Peer perform - knoxdaily.com
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty - Yahoo Finance
Repligen (RGEN) Price Target Adjusted by RBC Capital Amid Market Trends | RGEN Stock News - GuruFocus
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y - Barchart.com
Repligen Corporation (NASDAQ:RGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Repligen Corp (RGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.46%
0.05%
자본화:
|
볼륨(24시간):